Print this page    •   Back to Web version of article

Medical News
New WHO Guidelines Urge Phase-Out of Major HIV Drug

December 1, 2009

New HIV/AIDS treatment guidelines announced on Monday by the World Health Organization (WHO) include phasing out the use of stavudine (d4T) due to its side effects.

Stavudine has long-term, cumulative and irreversible side effects such as peripheral neuropathy (nerve disorder characterized by numbness, weakness and burning pain of hands and feet), and lipoatrophy (loss of fat from specific parts of the body). While its use has declined globally from about 80 percent of people taking ARVs in 2006, about half of patients still are using a d4T-containing regimen, WHO said.

Marketed by Bristol-Myers Squibb Co. as Zerit in the United States, d4T is manufactured in generic forms by Indian firms Cipla Ltd., Aurobindo Pharma Ltd., and Strides Arcolab Ltd. Because it is relatively cheap and easy to use, d4T is a widely prescribed first-line AIDS drug in low- and medium-income countries.

WHO's new guidelines propose that countries "progressively phase out the use of stavudine as a preferred first-line therapy option and move to less toxic alternatives such as zidovudine (AZT) and tenofovir (TDF)," which are comparable in terms of efficacy. However, while safer than d4T, AZT and TDF are currently more expensive first-line therapies, WHO acknowledged.

WHO called on countries using d4T to draw up plans to move toward AZT- or TDF-based first-line regimens, based on the assessment of cost and feasibility. WHO also said it would assist countries in creating phase-out plans that would not jeopardize treatment access or sustainability.

"[D4T] is the most widely used," said Dr. Siobhan Crowley of WHO's HIV/AIDS department. "There is a trend moving away from it. We think it will take some time."

Back to other news for December 2009

Excerpted from:
11.29.2009; Stephanie Nebehay

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.